Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Medical experts across neurology, gerontology, and primary care are increasingly advocating for improved cognitive screening protocols in standard healthcare settings. Currently, millions of Americans with early-stage cognitive decline go undiagnosed during routine doctor visits because many primary care physicians lack standardized screening tools or the time to administer them effectively.
A patient in her mid-60s might visit her family doctor multiple times complaining of memory problems, yet leave without a formal cognitive assessment—only to receive a dementia diagnosis years later when symptoms have progressed significantly and opportunities for early intervention have passed. The call for improved screening stems from a growing consensus that early detection of cognitive impairment offers patients and families a critical window to plan, access treatments that may slow decline, and modify lifestyle factors. Experts point to evidence showing that cognitive decline often begins 10-20 years before a dementia diagnosis, making the intermediate stage between normal aging and full dementia a crucial target for intervention.
Table of Contents
- Why Are Healthcare Providers Missing Early Signs of Cognitive Decline?
- Current Screening Methods Have Real Limitations
- Blood Tests and Biomarkers May Transform Early Detection
- Cognitive Screening Should Be Accessible, Not Just Available
- Language and Cultural Barriers Complicate Fair Screening
- Training Healthcare Providers Is Essential
- The Future of Dementia Screening and Early Detection
- Conclusion
Why Are Healthcare Providers Missing Early Signs of Cognitive Decline?
Primary care physicians encounter patients with cognitive concerns regularly, yet systematic screening remains inconsistent across medical practices. Many doctors rely on informal conversation and observation rather than validated screening tools, which can miss subtle changes that patients themselves haven’t fully recognized. The Mini-Cog test and Montreal Cognitive Assessment exist as evidence-based screening instruments, but they require 10-15 minutes to administer—a luxury many busy practices cannot afford given standard appointment lengths and competing clinical demands.
Time constraints represent one barrier, but lack of training is another significant factor. Many primary care doctors completed their medical education before cognitive screening protocols were standardized, and continuing education on dementia screening remains limited. One 2023 study found that fewer than 40% of primary care physicians reported confidence in conducting cognitive assessments, yet these same physicians are often the first medical contact for older adults experiencing memory problems. Without structured guidance and clear referral pathways, many doctors default to reassuring patients that occasional forgetfulness is normal aging—which is sometimes true, but misses the cases where it represents pathological decline.
Current Screening Methods Have Real Limitations
Existing cognitive screening tools used in clinical settings have meaningful gaps that experts are working to address. The Montreal Cognitive Assessment, while more comprehensive than older tests, can be influenced by education level, language, and cultural factors, potentially leading to both false positives in highly educated patients and missed diagnoses in those with limited formal education. A Mexican-American patient taking the assessment in English may score lower on language-heavy sections not because of cognitive decline, but because of language processing differences—leading to unnecessary worry or further testing.
Moreover, current screening approaches typically occur after a patient has already expressed concern, making them reactive rather than proactive. Dementia experts argue for earlier, more systematic screening beginning in the early 60s for all patients, similar to how blood pressure and cholesterol are monitored routinely. This shift would require infrastructure changes: integrating simple cognitive questions into annual wellness visits, training non-physician staff to administer initial screens, and establishing clear referral protocols for neuropsychological testing when concerns emerge. Without these system-level changes, screening remains ad hoc and easily deprioritized.
Blood Tests and Biomarkers May Transform Early Detection
Recent advances in blood-based biomarkers for Alzheimer’s disease represent a significant shift in early detection possibilities. Tests measuring phosphorylated tau, phosphorylated amyloid-beta, and neurofilament light chain can now identify brain changes associated with Alzheimer’s disease years before cognitive symptoms appear. These biomarkers offer the possibility of detecting pathological changes in people who still perform normally on cognitive tests—a genuine breakthrough for early intervention. However, biomarker testing introduces new complexity.
A 55-year-old with an abnormal blood biomarker faces a difficult situation: she has evidence of Alzheimer’s pathology in her brain, but no symptoms and no certainty that she will develop dementia in her lifetime. Experts point out that positive biomarkers do not automatically predict future dementia diagnosis, and mass screening of asymptomatic people without symptoms raises questions about medicalization and psychological burden. Some people would benefit from this information and use it to make informed lifestyle and medical decisions; others would experience anxiety without clear benefit. The healthcare system must develop clear guidelines about who should be screened and what counseling should accompany biomarker results.
Cognitive Screening Should Be Accessible, Not Just Available
Access to screening remains deeply unequal across demographic and geographic lines. Rural patients often lack access to neuropsychologists for comprehensive testing, forcing them to rely on primary care physicians with less specialized training. Older adults without reliable transportation, those living in poverty without paid time off work for medical appointments, and those in medically underserved communities face practical barriers to screening even when services theoretically exist. A 70-year-old living in a rural area 90 minutes from the nearest neuropsychologist faces very different practical barriers than someone living in a major metropolitan area.
Experts recommend expanding screening access through telehealth platforms, training geriatric specialists and nurse practitioners to conduct initial assessments, and integrating screening into routine wellness visits at primary care clinics where patients already go. Some innovative practices are using brief computerized cognitive assessments that patients can complete in the waiting room before seeing the doctor, freeing up appointment time while generating objective data. These approaches work better in some settings than others—telehealth assumes reliable internet and comfort with technology, which not all older adults have. But the underlying principle that screening should be geographically and financially accessible remains central to experts’ recommendations.
Language and Cultural Barriers Complicate Fair Screening
Cognitive assessment tools developed and validated primarily on English-speaking, educated populations often perform poorly for immigrants, people whose first language is not English, and those from different cultural backgrounds. Someone assessed on memory for word lists, clock-drawing, and other culturally-specific tasks may appear cognitively impaired when they are actually managing well in their native language and cultural context. Hispanic, Asian-American, and other non-dominant racial groups are underrepresented in cognitive research, meaning screening tools are less thoroughly validated for these populations. This limitation has real consequences.
Older adults from minority communities may be over-diagnosed with dementia when screened with culturally inappropriate tools, leading to unnecessary worry and medical intervention. Conversely, when screening tools are administered only in English to someone with limited English proficiency, genuine cognitive decline may be masked. Experts call for development of validated cognitive screening tools for diverse populations, bilingual assessment options, and training for clinicians in cultural humility and the limitations of current assessment approaches. This work is underway but remains incomplete, leaving current screening practices vulnerable to perpetuating health disparities.
Training Healthcare Providers Is Essential
Experts emphasize that improved screening tools mean little without providers trained to use them correctly and interpret results appropriately. Medical schools and residency programs are increasingly incorporating dementia screening and diagnosis into curricula, but this training remains inconsistent. A primary care physician who completed training 15 years ago likely received minimal dementia education and must rely on continuing education and self-directed learning to stay current with screening advances.
Healthcare systems are investing in targeted training programs, dementia champions within clinics, and decision-support tools that prompt providers to screen during appropriate visits. One successful model involves training nurses or medical assistants to conduct initial cognitive screening, freeing physicians to focus on discussing results and next steps. These approaches improve screening rates and early detection compared to standard practice, but they require institutional commitment and resources that smaller practices may struggle to allocate.
The Future of Dementia Screening and Early Detection
Looking forward, experts anticipate that cognitive screening will become as routine as blood pressure monitoring within the next decade, particularly as blood-based biomarkers become more widely available and less expensive. Integrated screening protocols combining brief cognitive assessment with biomarker testing may become standard in annual wellness visits for older adults, providing earlier identification of people at risk for cognitive decline.
This shift will require continued investment in provider training, development of culturally appropriate assessment tools, expansion of telehealth and community-based screening capacity, and thoughtful public health messaging about what early detection means and what people can do with that information. The field is moving toward prevention and early intervention rather than waiting for symptoms to become severe enough to force a diagnosis.
Conclusion
The experts’ call for improved cognitive screening reflects mounting evidence that early detection of cognitive decline offers meaningful opportunities for intervention, care planning, and potentially disease-modifying treatments. Current barriers—time constraints in clinical practice, gaps in provider training, limited access in rural and underserved areas, and cultural limitations of existing assessment tools—are substantial but addressable through systemic change and investment.
If you or a family member is concerned about cognitive changes, don’t wait for a diagnosis to emerge from informal observation. Ask your primary care doctor specifically about cognitive screening, seek evaluation from a neuropsychologist or geriatric specialist if you have concerns, and consider blood-based biomarker testing if it becomes available through your healthcare system. Early evaluation provides clarity, access to supportive care, and time to plan for the future.
